537 related articles for article (PubMed ID: 34767021)
1. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
[TBL] [Abstract][Full Text] [Related]
2. Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
Jiménez-Alcaide E; García-Fuentes C; Hernández V; De la Peña E; Pérez-Fernández E; Castro A; Caballero-Perea B; Guijarro A; Llorente C
Prostate; 2021 Dec; 81(16):1349-1354. PubMed ID: 34517429
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
5. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
6. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
Sari Motlagh R; Abufaraj M; Karakiewicz PI; Rajwa P; Mori K; Mun DH; Shariat SF
World J Urol; 2022 Apr; 40(4):907-914. PubMed ID: 34477955
[TBL] [Abstract][Full Text] [Related]
7. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
[TBL] [Abstract][Full Text] [Related]
8. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
[TBL] [Abstract][Full Text] [Related]
9. Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan.
Liao KM; Huang YB; Chen CY; Kuo CC
BMC Cancer; 2019 Dec; 19(1):1263. PubMed ID: 31888558
[TBL] [Abstract][Full Text] [Related]
10. Effects of Androgen Deprivation Therapy on COVID-19 in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.
Karimi A; Nowroozi A; Alilou S; Amini E
Urol J; 2021 Jul; 18(6):577-584. PubMed ID: 34302737
[TBL] [Abstract][Full Text] [Related]
11. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
[TBL] [Abstract][Full Text] [Related]
13. Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation.
Seikkula H; Boström PJ; Seppä K; Pitkäniemi J; Malila N; Kaipia A
BMC Urol; 2020 Mar; 20(1):25. PubMed ID: 32164671
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy and cardiovascular risk.
Punnen S; Cooperberg MR; Sadetsky N; Carroll PR
J Clin Oncol; 2011 Sep; 29(26):3510-6. PubMed ID: 21844498
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study.
Wu FJ; Li IH; Chien WC; Shih JH; Lin YC; Chuang CM; Cheng YD; Kao LT
BMJ Open; 2020 Mar; 10(3):e034202. PubMed ID: 32213519
[TBL] [Abstract][Full Text] [Related]
16. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
18. Association Between Androgen Deprivation Therapy and Risk of Dementia.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Leeper NJ; Shah NH
JAMA Oncol; 2017 Jan; 3(1):49-55. PubMed ID: 27737437
[TBL] [Abstract][Full Text] [Related]
19. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract][Full Text] [Related]
20. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
